Skip to content
DataLookout
Menu

QL1706+AG+SBRTNCT07938658

Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

ORR
Timeframe: From enrollment to the end of combination treatment at 8 weeks

Secondary (3)

PFS
OS
AE

Arms and interventions

QL1706 combined with AG and SBRTExperimental

Receive QL1706 through a vein (by intravenous infusion) once every 3 weeks Receive 2 chemotherapy drugs through a vein on days 1 and 8 of every 3-week cycle, for 2 cycles. The 2 drugs are gemcitabine and nab-paclitaxel Then receive SBRT to the pancreatic cancer, given about every other day over about 2 weeks, together with 2 more cycles of QL1706 and chemotherapy.

Drugs: Iparomlimab and Tuvonralimab Injection (QL1706)

Sites

1 site in 1 country

  • Tongji Hospital, Tongji Medical College, HUSTWuhan, Hubei, China